drugset / Trial / NCT00127036
Trial for Microarray Analysis of Colon Cancer Outcome-A (MACCO-A)
Phase 2
Terminated
65 enrolled
H. Lee Moffitt Cancer Center and Research Institute
Roche Pharma AG · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to determine if the investigators can predict the sensitivity or resistance of colon cancer to the two available first line chemotherapy agents.
Timeline
- Start
- 2003-10
- Primary completion
- 2010-12
- Completion
- 2010-12
Outcome
Outcome not reported
Stopped: “drug now on market”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 7.5 mg/kg | Intravenous |
| Subject | Capecitabine | Small molecule | 825 mg/m2 | Oral |
| Subject | Irinotecan | Small molecule | 240 mg/m2 | Intravenous |
| Subject | Oxaliplatin | Small molecule | 130 mg/m2 | Intravenous |